Search clinical trials for: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes

Total 248 results

Sumithira Vasu

Recruiting

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Cytomegalovirus | Adenovirus | Donor | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Solid Organ Transplantation Recipient

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cytomegaloviral Infection

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia and other conditions

United States
Milton S. Hershey Medical Center
National Cancer Institute (NCI)

Unknown

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Cancer

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)

Brain Cancer | Glioblastoma Multiforme | GBM

United States
Atara Biotherapeutics

No longer available

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

CMV Viremia | CMV Disease
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Hematopoietic and Lymphoid Cell Neoplasm | Immunocompromised

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Alabama at Birmingham

Withdrawn

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

Lymphoma | Leukemia

United States
New York Medical College
Johns Hopkins University; M.D. Anderson Cancer Center; Baylor College of Medicine and other collaborators

Terminated

Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

Hodgkins Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Acquired Immunodeficiency Syndrome | BK Virus Infection | Merkel Cell Carcinoma | Human Immunodeficiency Virus | Malignant Neoplasm | JC Virus Infection | Merkel Cell Polyomavirus Infection | Viral Encephalitis

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Terminated

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma (ALDI)

Non-Hodgkin Lymphoma | Hodgkins Lymphoma

United States
M.D. Anderson Cancer Center
Miltenyi Biotec B.V. & Co. KG

Completed

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Viral Specific T Cell Therapy for COVID-19 Related Pneumonia

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Jessie L. Alexander

Active, not recruiting

Viral Specific T-Lymphocytes to Treat Adenovirus or CMV

Cytomegalovirus Infections | Adenovirus

United States
Milton S. Hershey Medical Center

Completed

Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants

Cytomegalovirus Infections

United States
New York Medical College
Johns Hopkins University; University of Colorado, Denver; Children's Hospital... and other collaborators

Recruiting

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Primary Immune Deficiency Disorder | Adenovirus

United States
New York Medical College
Johns Hopkins University; Children's Hospital of Philadelphia; Washington University... and other collaborators

Recruiting

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Primary Immune Deficiency Disorder | Cytomegalovirus Infections

United States
University of Louisville
Penn State University

Completed

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | BK Virus Infection | Symptomatic COVID-19 Infection Laboratory-Confirmed | Adenovirus Infection | Cytomegaloviral Infection | JC Virus Infection

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (TGF-beta)

Lymphoma | Lymphoma, Non-Hodgkin | Relapse | Hodgkin's Disease

United States
Medical College of Wisconsin

Completed

Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV (ACE)

Epstein-Barr Virus Infections | Cytomegalovirus Infections | Adenovirus

United States
Shanghai General Hospital, Shanghai Jiao Tong University...
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Completed

CMV-CTL for the Treatment of CMV Infection After HSCT

Cytomegalovirus Infections | Hematological Disease

China
The First People's Hospital of Changzhou

Active, not recruiting

Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer

Gastric Cancer
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (ANGELA)

Hodgkin Disease | Non-Hodgkins Lymphoma

United States
Children's National Research Institute
M.D. Anderson Cancer Center

Completed

Cytotoxic T Cells to Prevent Virus Infections

CMV | EBV | Adenovirus Infections

United States
Yu Fenglei
Hunan Zhaotai Yongren Medical Innovation Co. Ltd.; Hunan Yongren Medical Innovation...

Unknown

Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Children's National Research Institute

Active, not recruiting

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (IMPACT)

Medulloblastoma, Childhood | Embryonal Tumor With Multilayered Rosettes | Pineoblastoma | Embryonal Tumor of CNS | Atypical Teratoid/Rhabdoid Tumor of CNS

United States
New York Medical College
Children's Hospital of Philadelphia; Washington University School of Medicine; University of California, Los Angeles and other collaborators

Recruiting

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Epstein-Barr Virus Infections | Primary Immune Deficiency Disorder

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Tianjin Medical University Cancer Institute and...

Unknown

Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer (AAV-DC-CTL)

Stage IV Gastric Cancer

China
Atara Biotherapeutics
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Completed

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
Tianjin Medical University Cancer Institute and...

Unknown

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Non-small Cell Lung Cancer | Second-line Treatment

China
Beijing Friendship Hospital

Recruiting

Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT

Chronic Active Epstein-Barr Virus Infection | Virus-Associated Hemophagocytic Syndrome

China
M.D. Anderson Cancer Center
Ziopharm Oncology

Completed

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Lymphoma | Leukemia

United States
Universitätsklinikum Köln
Hannover Medical School; Miltenyi Biomedicine GmbH; ZKS Köln

Terminated

Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19 (ACT-COVID-19)

Moderate COVID-19-infection

Germany
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy... and other collaborators

Completed

TAA-Specific CTLS for Solid Tumors (TACTASOM)

Rhabdomyosarcoma

United States
Children's Mercy Hospital Kansas City
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma (STALLONe)

Neuroblastoma

United States
Moscow Department of Health
Moscow State University of Medicine and Dentistry; National Research Center... and other collaborators

Completed

The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents

Covid19 | Respiratory Viral Infection

Russian Federation
Queensland Institute of Medical Research
Merck Sharp & Dohme LLC; Royal Brisbane and Women's Hospital; Princess Alexandra... and other collaborators

Recruiting

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP)

Glioblastoma Multiforme | Astrocytoma, Grade IV

Australia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Bellicum Pharmaceuticals

Withdrawn

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic... and other conditions

United States
Nelson Chao

Terminated

Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT

Cytomegalovirus Infections

United States
Atara Biotherapeutics
Merck Sharp & Dohme LLC

Terminated

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

United States
Paul Szabolcs

Enrolling by invitation

Anti-viral T-cell Therapy by Gamma Capture (Gamma Capture)

Epstein-Barr Virus Infections | Cytomegalovirus Infections | Adenovirus

United States
Atara Biotherapeutics

Terminated

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (EMBOLD)

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States, Australia, Canada
Nationwide Children's Hospital

Recruiting

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections (ADV-VSTS)

Adenovirus Infection

United States
University of Wisconsin, Madison

Recruiting

BK With VST for Kidney Transplant Patients

BK Virus Infection | Kidney Transplant Infection

United States
NeuroVita Clinic
Blokhin's Russian Cancer Research Center; Russian Foundation of Technological... and other collaborators

Unknown

Proteome-based Personalized Immunotherapy of Glioblastoma

Glioblastoma

Russian Federation

Search clinical trials for: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations